Mechanism of CoVID-19 induced hyperinflammation

死于新冠肺炎病毒通常是由急性呼吸衰竭和称为急性呼吸窘迫综合征或ARDS的病理生理过程引起的。这一疾病过程与炎症反应有关，最终导致肺泡内液体，导致呼吸衰竭。ARDS的继发性临床表现为噬血细胞性淋巴组织细胞增多症，这是一种以暴发性疾病(组织损伤)和致命性细胞因子风暴(高细胞分裂素血症)为特征的多器官衰竭的高炎症综合征。在与ENCYT Technologies Inc.的合作下，我们已经开发出一种新的治疗方法，将在出现呼吸窘迫初步迹象的新冠肺炎感染患者中消除这种致命的细胞因子风暴。

Death from the COVID-19 virus is typically caused by acute respiratory failure and the pathophysiologic process known as Acute Respiratory Distress Syndrome or ARDS. This disease process is associated with an inflammatory response that ultimately leads to fluid within the lung's alveoli leading to respiratory failure. A secondary clinical manifestation of ARDS is haemophagocytic lymphohistiocytosis which is a hyper-inflammatory syndrome characterized by a fulminant disease (tissue injury) and a fatal cytokine storm (hyper-cytokinemia) with multi-organ failure. In collaboration with ENCYT Technologies Inc., we have developed a novel treatment that will abrogate this fatal cytokine storm in COVID-19 infected patients developing initial signs of respiratory distress.